Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a personalized antisense oligonucleotide therapy for SCN2A-related epilepsy in children; the study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scn2a-related Epilepsy

Snippet

Sponsor: University of California, San Diego | Conditions: Genetic Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING